Your browser doesn't support javascript.
loading
Intratumoral immune activation with TLR4 agonist synergizes with effector T cells to eradicate established murine tumors.
Albershardt, Tina C; Leleux, Jardin; Parsons, Andrea J; Krull, Jordan E; Berglund, Peter; Ter Meulen, Jan.
Affiliation
  • Albershardt TC; Immune Design, a wholly-owned subsidiary of Merck & Co., Inc, Kenilworth, NJ USA.
  • Leleux J; Immune Design, a wholly-owned subsidiary of Merck & Co., Inc, Kenilworth, NJ USA.
  • Parsons AJ; Immune Design, a wholly-owned subsidiary of Merck & Co., Inc, Kenilworth, NJ USA.
  • Krull JE; Immune Design, a wholly-owned subsidiary of Merck & Co., Inc, Kenilworth, NJ USA.
  • Berglund P; Immune Design, a wholly-owned subsidiary of Merck & Co., Inc, Kenilworth, NJ USA.
  • Ter Meulen J; Immune Design, a wholly-owned subsidiary of Merck & Co., Inc, Kenilworth, NJ USA.
NPJ Vaccines ; 5(1): 50, 2020.
Article in En | MEDLINE | ID: mdl-32579133
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: NPJ Vaccines Year: 2020 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: NPJ Vaccines Year: 2020 Document type: Article